title: Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans.
abstract: The biological effects of dose-dependent inhibition of renin have rarely been extensively studied after oral (p.o.) dosing in humans. We studied remikiren (Ro42-4892), a selective renin inhibitor, in normal volunteers after activation of the renin-angiotensin system (RAS) based on salt depletion. Twelve normal men (28 +/- 9 years, 77 +/- 10 kg), comprising three consecutive dose panels of 4 subjects, received four treatments, double-blind and randomised 2 weeks apart: panel I, placebo (P), or 30, 100, and 300 mg, remikiren; panel II, placebo or 300, 600 mg, 1,000; panel III, placebo or 30, 600, and 1,000 mg. The RAS was activated by 40 mmol/day sodium diet plus frusemide (40 mg BDS), for 3 days before each study day. Data (mean +/- SD) were examined by repeated-measures analysis of variance (ANOVA). RAS activation was confirmed by 24-h urinary sodium excretion (screen, 142 +/- 74 mmol/24 h; prestudy, 66 +/- 33, 59 +/- 41, 78 +/- 4, 73 +/- 30 mmol/24 h) and increase in plasma renin activity (PRA) (screen, 0.8 +/- 0.3 ng AI/ml/h; before dosing, P, 6.5 +/- 3.1; 30 mg, 8.2 +/- 3; 100 mg, 9.4 +/- 5.7; 300 mg, 6.5 +/- 2.4; 600 mg, 5.2 +/- 2; 1,000 mg, 6.2 +/- 4.4 ng AI/ml/h).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland.
authors.forename: R J
authors.initials: RJ
authors.lastname: MacFadyen
authors.forename: C R
authors.initials: CR
authors.lastname: Jones
authors.forename: J K
authors.initials: JK
authors.lastname: Doig
authors.forename: H
authors.initials: H
authors.lastname: Birnbock
authors.forename: J L
authors.initials: JL
authors.lastname: Reid
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004573:Electrolytes / Q000378:metabolism; D004656:Enalapril / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006728:Hormones / Q000097:blood*; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019808:Losartan; D008297:Male; D012083:Renin / Q000097:blood; D012964:Sodium / Q000502:physiology*; D013777:Tetrazoles / Q000494:pharmacology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D004573:Electrolytes; D006728:Hormones; D007093:Imidazoles; D013777:Tetrazoles; D004656:Enalapril; D012964:Sodium; D012083:Renin; D019808:Losartan; C065581:remikiren